Global biotechnology company Amgen has revealed a significant investment plan, earmarking $650m to enhance its manufacturing operations in the US.

The investment aims to scale up the production of drugs at the company’s Juncos’ biologics production facility in Puerto Rico.

The company will also use the planned investment to incorporate the latest technologies across operational workflow and generate 750 new jobs, including positions in construction and specialised manufacturing sectors.

Amgen CEO and chairman Robert Bradway stated: "This expansion underscores Amgen's commitment to US biomanufacturing and to strengthening the resilience of our global supply chain.

"By growing our capacity to deliver innovative medicines with cutting-edge technology in our manufacturing plants, we will not only better serve patients but also create high-quality jobs that reinforce America's leadership in biotechnology."

Since the implementation of the US Tax Cuts and Jobs Act (TCJA) in 2017, the company has been focusing on fostering operations and innovation within the US, with investments surpassing $40bn in manufacturing and research and development.

Favourable tax reforms introduced by the TCJA, and further supported by the One Big Beautiful Bill Act of 2025, have enabled it to continue investing in the domestic sphere, particularly in science and manufacturing.

The latest US manufacturing network expansion plan is part of the company’s ongoing investment strategy, which has included recent projects such as California’s $600m science and innovation centre and expansions in Ohio and North Carolina, costing $900m and $1bn respectively.

Puerto Rico Department of Economic Development and Commerce Secretary Sebastián Negrón Reichard stated: "Puerto Rico boasts more than 60 years of expertise and excellence in the biopharmaceutical sector, supported by highly skilled talent and world-class infrastructure.

"This investment by Amgen is a testament to how committed we are to advancing a competitive and innovative ecosystem that allows global companies to grow and prosper in Puerto Rico."

Amgen is working on expanding its portfolio with a focus on treatments for conditions such as cancer, osteoporosis, heart disease, and rare and inflammatory diseases.

In January 2025, the company secured US Food and Drug Administration approval for its Lumakras and Vectibix combination therapy for adults with KRAS G12C-mutated metastatic colorectal cancer.